Thursday, January 03, 2019 4:30:05 PM
Chas ...dont have private messaging so will just send you this
https://www.washingtonexaminer.com/policy/economy/trump-economist-kevin-hassett-says-a-heck-of-a-lot-of-companies-besides-apple-will-suffer-china-fallout
Trumps Econ advisor ..Kevin Hassett acknowledges many US companies will suffer but thinks its worth it for the US in the long run.
note
"It is not going to be just Apple. I think that there are a heck of a lot of U.S. companies that have a lot of sales in China that are basically going to be watching their earnings being downgraded next year until we get a deal with China," Hassett, chairman of the White House's Council of Economic Advisers, said in an appearance on CNN.
So you and Tasty ...or do we refer to him as PE now ...should cheer up. As AMRN shareholders you're doing your part ...consider part of the slide in AMRN as " collateral damage ".
Kiwi
PS ..love that video from Ken Fisher in August ...you know the one that ends with him saying that since the tariffs have been announced ...stock market has pretty much been going up ......Hmmm...hows that playing out now
https://www.washingtonexaminer.com/policy/economy/trump-economist-kevin-hassett-says-a-heck-of-a-lot-of-companies-besides-apple-will-suffer-china-fallout
Trumps Econ advisor ..Kevin Hassett acknowledges many US companies will suffer but thinks its worth it for the US in the long run.
note
"It is not going to be just Apple. I think that there are a heck of a lot of U.S. companies that have a lot of sales in China that are basically going to be watching their earnings being downgraded next year until we get a deal with China," Hassett, chairman of the White House's Council of Economic Advisers, said in an appearance on CNN.
So you and Tasty ...or do we refer to him as PE now ...should cheer up. As AMRN shareholders you're doing your part ...consider part of the slide in AMRN as " collateral damage ".
Kiwi
PS ..love that video from Ken Fisher in August ...you know the one that ends with him saying that since the tariffs have been announced ...stock market has pretty much been going up ......Hmmm...hows that playing out now
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
